Status:
RECRUITING
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Glioblastoma
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Combined chemoradiation and radiofrequency electromagnetic field treatment for patients with glioblastoma
Detailed Description
Charité Universitätsmedizin Berlin is currently the only German University Hospital with an available capacitive radiofrequency electromagnetic field treatment device. While there is retrospective dat...
Eligibility Criteria
Inclusion
- Pathological evidence of newly diagnosed glioblastoma according to WHO classification criteria
- Patients 18 to 70 years of age with a WHO performance status of 2 or less
- All patients must sign written informed consent
- Adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥1,5 x 103/μL; platelet count, ≥100 x 103/μL; serum creatinine ≤1.7 mg/dL; total bilirubin \> upper limit of normal; AST or ALT ≤3 times the upper limit of normal)
- Patient must have received subtotal or gross total resection of the tumor
- MGMT-promotor methylated patients must have refused therapy according to the CeTeG/NOA-09 protocol (+ Lomustin)
- Patient must be planned for concomitant RCT with a total RT dose of 60 Gy over six weeks and temozolomide followed by six cycles of maintenance CT using temozolomide
Exclusion
- Previous cranial RT
- Cytostatic therapy / anti-angiogenic substances / CT or radiation therapy for cancer within the past 5 years
- History of cancers or other comorbidities that limit life expectancy to less than five years
- Postoperative evidence of increased intracranial pressure (midline shift \> 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
- Technical impossibility to use magnetic resonance imaging (MRI) or known allergies against MRI and/or computed tomography (CT) contrast agents
- Technical impossibility to use AM-RF-EMF (pacemaker, defibrillator or deep brain stimulator, metal implants)
- Participants of childbearing age unwilling to use or not capable of using effective contraception
- Pregnant patients
Key Trial Info
Start Date :
November 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 14 2029
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT06140875
Start Date
November 15 2023
End Date
May 14 2029
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitätsmedizin Berlin
Berlin, Germany, 13353